GSK and Amgen - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Amgen
Where: China, Brazil and India

Deal Size: $120 million

Details: A year before Amgen won approval of denosumab for postmenopausal women with osteoporosis, GlaxoSmithKline snagged marketing rights for the drug in China, Brazil and India--three of the largest emerging pharmaceutical markets. Additionally, GSK got rights to sell the drug in South Korea and all other markets where Amgen doesn't have a commercial presence.

Amgen and GSK also agreed to share commercialization of denosumab in Europe, Australia, New Zealand and Mexico. The Big Biotech got an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. Analysts estimate the drug could eventually reach up to $2 billion in annual sales.

GSK and Amgen - Top 5 Emerging Market Deals

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.